Objective To observe the clinical effect that Qi Jiao Sheng Bai capsule prevented and improved myelosuppression caused by PEG-IFN α-2a during the treatment of chronic hepatitis c. Methods 86 cases of chronic hepatitis c patients using PEG-IFN α-2a were randomly divided into two groups :46 cases in trial group and 40 cases in control group. Patients of two groups were given PEG-IFN α-2a (180 μg ),ih,qw,and ribavirin 400 mg,bid,po for antiviral treatment. Besides,the trial group combined with Qi Jiao Sheng Bai capsule 4 grain,tid. Before and after treatment, the routine blood HCV-RNA, liver/kidney function were tested once a week for 8 weeks. At the same time,the adverse reactions were observed. Results After eight weeks, in trail group, the number of neutrophile granulocyte were in the normal range, while it had mildly descendentce. The myelosuppression rate in the trail group was 34. 8%( 16/ 46 ), while it was 77. 5% ( 31/40 ) in control group. ( P < 0. 05 ). Mild and moderate myelosuppression rate in trail group were 26. 1% ( 12/46 ) and 6. 5% ( 3/46 ), while they were 47. 5% ( 19/40 )and 20. 0% ( 8/40 )in control group. Severe myelosuppression rate that need to stop treatment in trail group was 2. 2% ( 1/46 ), while it was 10% ( 4/40 ) in control group. Conclusion Qi Jiao Sheng Bai capsule can prevent and significantly improve myelosuppression caused by interferon treatment with little adverse effect. It is safe and effective to cure myelosuppression.%目的 观察应用芪胶升白胶囊预防和改善聚乙二醇干扰素α-2a注射液治疗慢性丙型肝炎所致骨髓抑制的临床疗效.方法 86例慢性丙型肝炎患者随机分为试验组46例,对照组40例.两组患者均应用聚乙二醇干扰素α-2a(180 μg),皮下注射,1次/周,同时加服利巴韦林500 mg/次,2次/d抗病毒治疗.试验组在对照组的基础上加用芪胶升白胶囊4粒/次,3次/d.治疗前及治疗后每周检查血常规、HCV-RNA、肝肾功能等,观察8周.同时观察芪胶升白胶囊的不良反应.结果 治疗8周结束后,试验组白细胞中性粒细胞绝对值在正常范围内,并无明显下降,对照组有轻度下降;且试验组骨髓抑制发生率为34.8%(16/46),对照组为77.5%(34/40),两组差异有显著性(P=0.001).其中轻度骨髓抑制发生率试验组为26.1%(12/46),对照组为47.5%;中度骨髓抑制发生率试验组为6.5%(3/46),对照组为20.0%(8/40);需要停止聚乙二醇干扰素α-2a治疗的重度骨髓抑制发生率试验组为2.2%(1/46),对照组为10%(4/40).结论 芪胶升白胶囊可预防并改善干扰素治疗慢性丙型肝炎所致的骨髓抑制,且安全无不良反应,值得推广使用.
展开▼
